Single cell landscape of sex differences in the different courses of multiple sclerosis

This study utilizes single-cell transcriptomics of over 48,000 central nervous system and 336,000 peripheral immune cells to construct a comprehensive molecular landscape of sex differences in multiple sclerosis, revealing distinct protective mechanisms in females and more severe cytolytic and mitochondrial profiles in males that could inform personalized therapeutic strategies.

The Gist

The Big Picture: Why Men and Women Experience MS Differently

Imagine Multiple Sclerosis (MS) as a chaotic storm hitting a city (the human body). The storm damages the power lines (nerves) and the insulation around them (myelin).

We know from statistics that this storm hits women more often (2 to 3 times more likely), but when it hits men, the damage tends to be deeper, faster, and harder to recover from. Men often lose their ability to walk or think clearly sooner than women do.

The Question: Why? Is it just hormones? Is it genetics?
The Study's Answer: The researchers looked at the "microscopic city" inside the body, cell by cell, to see exactly how the storm affects men and women differently. They used a high-tech camera (single-cell sequencing) to take a snapshot of every single cell in the brain and blood of MS patients.

---

Part 1: The Brain City (Central Nervous System)

Focus: Secondary Progressive MS (The later, slower-burning stage)

Think of the brain as a city with different neighborhoods: Neurons (the power lines), Astrocytes (the maintenance crew), Microglia (the security guards), and Oligodendrocytes (the insulation repair crew).

1. The Neurons (The Power Lines)

• Women's Neurons: They are like a city with a smart emergency response team. When the storm hits, women's neurons turn on "protective shields." They increase the production of "calming chemicals" (GABA) to stop the power lines from getting too excited (excitotoxicity). It's like a fire department that arrives early to put out sparks before they become a blaze.
• Men's Neurons: They are like a city with overworked generators. Men's neurons seem to be running on high energy but without the brakes. They are pumping out "exciting chemicals" (glutamate) that can actually burn out the power lines faster. This might explain why men's brains deteriorate more quickly.

2. The Repair Crew (Oligodendrocytes)

• Women: They are the master builders. They have more tools and blueprints to fix the insulation (myelin) around the wires. They are actively trying to rebuild the city.
• Men: They are trying to build, but they seem to be using different, less efficient tools. They are also more focused on clearing away the debris (dead cells) rather than rebuilding the structure.

3. The Security Guards (Microglia)

• Women: They are clean-up crews focused on recycling. They are very good at eating up the damaged myelin debris to make space for new repairs.
• Men: They are heavy-duty demolition crews. They are focused on clearing out the mess, but they might be clearing it too aggressively, or perhaps they are getting clogged up with the debris (lipid droplets), making them less effective at helping the neurons.

The Takeaway: In the later stages of MS, women's brains seem to have a better "repair and protect" strategy, while men's brains are more prone to "burnout" and rapid decline.

---

Part 2: The Blood Army (Peripheral Immune System)

Focus: Relapsing-Remitting MS (The early, flare-up stage)

Now, let's look at the immune system, which is like the army sent to fight the storm.

1. The Female Army (Relapsing-Remitting MS)

• The Strategy: The female immune system is like a loud, active protest. It is very noisy and aggressive.
• The Leader: The army is led by a commander called AP-1. This commander screams "Attack!" very loudly, causing a lot of inflammation.
• The Result: This explains why women get MS more often and have more frequent "relapses" (storms). The army is over-reacting, causing a lot of noise and damage in the short term, but it's not necessarily destroying the city as fast as the male army.

2. The Male Army (Relapsing-Remitting MS)

• The Strategy: The male immune system is like a silent, high-tech machine. It isn't as loud, but it has a different problem.
• The Engine: The male soldiers (T-cells) have broken engines (mitochondria). They are burning fuel inefficiently, creating toxic exhaust (reactive oxygen species).
• The Result: This toxic exhaust poisons the city from the inside, leading to faster long-term damage, even if the "noise" (inflammation) isn't as loud as in women.

3. The Male Army (Primary Progressive MS)

• The Strategy: In the most severe, steady-decline form of MS (PPMS), the male army changes tactics completely.
• The Weapon: The male CD8+ T-cells (the elite assassins) become cytolytic killers. They don't just fight; they actively destroy the city's infrastructure using "perforin" and "granzyme" (biological drills and explosives).
• The Result: This aggressive, silent destruction is likely why men with PPMS lose function so rapidly. They aren't just inflamed; they are actively dismantling the brain.

---

Part 3: The "ID Card" of the Disease

The researchers found a special 67-gene signature. Think of this as a barcode.

• If you scan a patient's blood cells and see this barcode, you can tell if they are likely to have the "Relapsing" type (more common in women) or the "Progressive" type (more common in men).
• This is huge because it means doctors might one day be able to predict how a patient's disease will behave just by looking at their immune cells, allowing for personalized treatment plans.

The Bottom Line

This study is like a detailed map of the battle between MS and the human body, showing that men and women fight the war on different battlefields with different weapons.

• Women tend to fight with a loud, inflammatory army that causes frequent storms but has better brain repair crews.
• Men tend to fight with a silent, toxic army that causes less noise but burns out the brain's power lines faster and destroys the city's infrastructure more aggressively.

Why does this matter?
For decades, doctors have treated MS the same way for everyone. This research suggests that we need sex-specific treatments.

• We might need to give women drugs that calm down the "loud protest" (inflammation).
• We might need to give men drugs that fix their "broken engines" (mitochondria) or stop their "assassins" (CD8+ T-cells) from destroying the brain.

By understanding these differences, we can move from a "one-size-fits-all" approach to a personalized medicine approach that saves more brains, faster.

Technical Summary

1. Problem Statement

Multiple Sclerosis (MS) is a chronic autoimmune and neurodegenerative disease characterized by a complex progression from inflammatory relapses (Relapsing-Remitting MS, RRMS) to progressive neurodegeneration (Secondary Progressive MS, SPMS and Primary Progressive MS, PPMS). A well-documented epidemiological disparity exists: females are 2–3 times more likely to develop MS and suffer more frequent relapses, while males experience faster neurodegeneration and greater disability. Despite these clinical observations, the cell-type-specific molecular mechanisms driving these sex differences across different disease stages remain poorly understood. Previous bulk RNA-seq studies averaged signals across heterogeneous cell populations, obscuring specific cellular responses. This study aims to resolve these gaps by constructing a comprehensive single-cell transcriptomic atlas of sex differences in both the Central Nervous System (CNS) and peripheral immune system across MS subtypes.

2. Methodology

The study employed a rigorous in-silico approach analyzing publicly available single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) datasets.

• Data Sources:
  • CNS (SPMS): Post-mortem brain tissue (snRNA-seq) from Schirmer et al.
  • Peripheral Blood (RRMS & PPMS): PBMCs (scRNA-seq) from Kaufmann et al.
  • Validation: An independent CNS cohort (MacNair et al.) was used to validate neuronal findings.
• Preprocessing & Annotation:
  • Standardized quality control (filtering low-quality cells/nuclei, mitochondrial ratio, doublet detection).
  • Normalization (deconvolution approach), dimensionality reduction (PCA, tSNE, UMAP), and clustering.
  • Cell type annotation using reference datasets (BRETIGEA for CNS; SingleR/MonacoImmuneData for blood).
  • Cell Types Analyzed: Neurons, Astrocytes, Microglia, Oligodendrocytes, OPCs (CNS); CD4+ T, CD8+ T, NK cells, Monocytes, B cells, Dendritic cells (Blood).
• Statistical Framework:
  • Three distinct comparisons were performed for each cell type:
    1. IDF: Impact of Disease in Females (MS.Female vs. Control.Female).
    2. IDM: Impact of Disease in Males (MS.Male vs. Control.Male).
    3. SDID: Sex-Differential Impact of Disease ((MS.Female - Control.Female) - (MS.Male - Control.Male)).
  • Differential Expression: Hurdle models (MAST) with covariates (age, batch, cell cycle).
  • Functional Analysis: Gene Ontology (GO) enrichment, Protein-Protein Interaction (PPI) networks (STRINGdb), and Signaling Pathway activation (KEGG via hipathia).
  • Cell-Cell Communication: Inferred using the CellChat algorithm to quantify ligand-receptor interaction strengths.
• Resource: All results are accessible via an interactive web tool: https://bioinfo.cipf.es/cbl-atlas-ms/.

3. Key Contributions

• First Single-Cell Sex Atlas: This is the first study to generate a comprehensive, cell-type-resolved transcriptomic atlas of sex differences specifically stratified by MS disease course (RRMS, SPMS, PPMS).
• Mechanistic Insights: It moves beyond general prevalence statistics to identify specific molecular pathways (e.g., excitotoxicity compensation, mitochondrial dysfunction, cytolytic activity) that differ between sexes in specific cell types.
• Subtype Stratification: The study demonstrates that sex-differential gene signatures can effectively cluster immune cells by disease subtype (RRMS vs. PPMS), suggesting a molecular basis for clinical heterogeneity.
• Open Science: The authors provide a user-friendly web platform and open-source code to facilitate further research and biomarker discovery.

4. Key Results

A. Central Nervous System (SPMS Post-Mortem Brain)

• Neurons (Excitotoxicity vs. Protection):
  • Females: Upregulated genes related to GABAergic signaling (inhibitory) and glutamate receptors, suggesting a compensatory mechanism to counteract excitotoxicity.
  • Males: Upregulated genes for glutamatergic signaling (excitatory) and ATPase subunits involved in vesicle biogenesis, potentially increasing susceptibility to excitotoxic damage.
• Astrocytes & Microglia (Stress & Myelin):
  • Females: Enhanced expression of neuroprotective genes (e.g., NEAT1, LINC-PINT) and genes involved in hypoxia response and lipid metabolism, potentially aiding myelin clearance.
  • Males: Increased expression of APOE (linked to lipid droplet accumulation and cognitive decline) and genes related to protein degradation/apoptosis.
• Oligodendrocytes (OPCs):
  • Females: Stronger activation of PDGF and FGF signaling pathways (specifically PDGFC-PDGFRB interactions) and upregulation of differentiation markers (QKI), suggesting a more robust capacity for remyelination.
  • Males: Less pronounced signaling changes in OPCs compared to females.

B. Peripheral Immune System (RRMS)

• Females (Inflammatory Core):
  • Exhibit a broader transcriptomic alteration than males.
  • A central hub of AP-1 transcription factors (FOS, JUN, JUNB, JUND) drives a pro-inflammatory network involving cell adhesion and cytokine signaling (e.g., IL6).
• Males (Mitochondrial Dysfunction):
  • Adaptive immune cells (CD4+, CD8+, NK) show significant upregulation of mitochondrial electron transport chain genes.
  • This suggests increased reactive oxygen species (ROS) production, potentially driving the rapid neurodegeneration observed in males.

C. Peripheral Immune System (PPMS)

• CD8+ T Cells (Cytolysis vs. Homeostasis):
  • Males: Exhibit a highly activated, cytolytic profile (Granzyme/Perforin pathways, calcium regulation), which may directly contribute to axonal damage and rapid progression.
  • Females: Show upregulation of genes related to cellular homeostasis, protein translation regulation, and mitochondrial maintenance, suggesting a protective or restorative state.
• Subtype Clustering: A signature of 67 genes successfully clustered immune cells by disease subtype (RRMS vs. PPMS) rather than just by cell type. RRMS signatures were female-dominant (inflammation), while PPMS signatures were male-dominant (metabolic/cytolytic).

D. Antigen Presentation & Viral Response

• HLA Dynamics: Significant sex differences were found in Major Histocompatibility Complex (MHC) interactions.
  • RRMS Females: Stronger MHC-II interactions and viral response signatures.
  • PPMS Males: Stronger MHC-I interactions and viral defense signatures.
• HLA-DRB5: Showed increased expression in RRMS females and PPMS males, potentially influencing autoimmunity and disease severity.

5. Significance and Implications

• Precision Medicine: The findings argue against a "one-size-fits-all" approach to MS treatment. Therapies targeting inflammation (AP-1, cytokines) may be more critical for females in early stages (RRMS), while therapies targeting mitochondrial health or cytolytic T-cell activity may be crucial for males in progressive stages (PPMS).
• Neuroprotection: The identification of female-specific compensatory mechanisms (e.g., GABA upregulation, QKI in OPCs) highlights potential therapeutic targets to mimic these protective effects in males or in progressive stages.
• Biomarker Development: The 67-gene signature distinguishing RRMS and PPMS based on sex-differential profiles offers a potential tool for early diagnosis and prognosis.
• Future Research: The study underscores the need to investigate sex-specific metabolic profiles and mitochondrial status in CNS-infiltrating T cells, as well as the role of sex hormones in regulating these specific pathways.

In conclusion, this paper provides a foundational resource that redefines the understanding of MS pathology by integrating sex, cell type, and disease stage, offering a roadmap for developing sex-specific therapeutic strategies.